TickerFacts.

Company research / EDIT

Editas Medicine, Inc. (EDIT)

Build a valuation ↗↓ Download CSV

CIK 0001650664 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Editas Medicine, Inc. reported revenue of $40.52M. Revenue grew 25.4% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $47.01M.

Key ratios (year ended 2025-12-31)

-394.9%
Operating margin
-395.0%
Net margin
-586.6%
Return on year-end equity
25.4%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-08

Headquarters locality: Cambridge · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$47.01M$40.52M$32.31M$78.12M$19.71M$25.54M$90.73M$20.53M$31.94M$13.73M$6.05M
R&D Expense$84.96M$89.95M$199.25M$177.65M$174.96M$142.51M$158.00M$96.90M$90.65M$83.16M$56.98M
Operating Income-$75.86M-$160.01M-$251.15M-$169.18M-$225.95M-$193.15M-$134.84M-$140.92M-$113.73M-$119.93M-$97.19M
Net Income-$73.95M-$160.06M-$237.09M-$153.22M-$220.43M-$192.50M-$115.98M-$133.75M-$109.95M-$120.32M-$97.18M
EPS (Diluted)n/a-$1.80-$2.88-$2.02-$3.21-$2.85-$1.98-$2.68n/an/an/a
Total Assets$237.36M$186.53M$341.59M$499.15M$514.32M$677.48M$572.60M$508.88M$420.39M$373.26M$229.18M
Total Liabilities$132.08M$159.25M$207.31M$150.06M$153.64M$123.84M$179.02M$246.45M$184.22M$165.18M$94.58M
Long-Term Debtn/an/a$57.43Mn/an/an/an/an/an/an/an/a
Shareholders' Equity$105.28M$27.29M$134.27M$349.10M$360.68M$553.64M$393.59M$262.44M$236.16M$208.08M$134.61M
Cash & Equivalents$181.81M$146.65M$131.54M$123.65M$141.52M$203.52M$139.68M$238.18M$134.78M$146.63M$185.32M
Operating Cash Flow-$119.86M-$165.24M-$210.28M-$132.18M-$177.35M-$163.80M-$179.84M-$40.67M-$45.71M-$9.42M-$50.25M
Capital Expenditures$691.0K$607.0K$8.83M$4.72M$4.12M$7.98M$7.16M$6.17M$4.75M$2.06M$3.49M
Free Cash Flow-$120.55M-$165.85M-$219.11M-$136.90M-$181.47M-$171.78M-$187.00M-$46.84M-$50.46M-$11.48M-$53.74M
Shares Outstanding97.87M97.87M82.73M81.77M68.85M68.44M62.56M54.36M48.76M44.51M35.82M
Weighted Average Diluted Sharesn/a88.75M82.34M75.97M68.66M67.62M58.61M49.98Mn/an/an/a
EPS (Basic)n/a-$1.80-$2.88-$2.02-$3.21-$2.85-$1.98-$2.68n/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView